308 related articles for article (PubMed ID: 26062848)
21. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
[TBL] [Abstract][Full Text] [Related]
22. BEX1 acts as a tumor suppressor in acute myeloid leukemia.
Lindblad O; Li T; Su X; Sun J; Kabir NN; Levander F; Zhao H; Lu G; Rönnstrand L; Kazi JU
Oncotarget; 2015 Aug; 6(25):21395-405. PubMed ID: 26046670
[TBL] [Abstract][Full Text] [Related]
23. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
[TBL] [Abstract][Full Text] [Related]
24. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
[TBL] [Abstract][Full Text] [Related]
25. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
Shankar DB; Li J; Tapang P; Owen McCall J; Pease LJ; Dai Y; Wei RQ; Albert DH; Bouska JJ; Osterling DJ; Guo J; Marcotte PA; Johnson EF; Soni N; Hartandi K; Michaelides MR; Davidsen SK; Priceman SJ; Chang JC; Rhodes K; Shah N; Moore TB; Sakamoto KM; Glaser KB
Blood; 2007 Apr; 109(8):3400-8. PubMed ID: 17209055
[TBL] [Abstract][Full Text] [Related]
26. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
27. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
28. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
29. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
[TBL] [Abstract][Full Text] [Related]
30. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
31. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
[TBL] [Abstract][Full Text] [Related]
32. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.
Sallmyr A; Fan J; Datta K; Kim KT; Grosu D; Shapiro P; Small D; Rassool F
Blood; 2008 Mar; 111(6):3173-82. PubMed ID: 18192505
[TBL] [Abstract][Full Text] [Related]
33. Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.
Skwarska A; Augustin E; Beffinger M; Wojtczyk A; Konicz S; Laskowska K; Polewska J
Biochem Pharmacol; 2015 Jun; 95(4):238-52. PubMed ID: 25896848
[TBL] [Abstract][Full Text] [Related]
34. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
35. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations.
Seedhouse CH; Pallis M; Grundy M; Shang S; Russell NH
Br J Haematol; 2009 Dec; 147(5):653-61. PubMed ID: 19775300
[TBL] [Abstract][Full Text] [Related]
36. FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.
Chu SH; Heiser D; Li L; Kaplan I; Collector M; Huso D; Sharkis SJ; Civin C; Small D
Cell Stem Cell; 2012 Sep; 11(3):346-58. PubMed ID: 22958930
[TBL] [Abstract][Full Text] [Related]
37. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
38. Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti-Acute Myeloid Leukemia Efficacy In Vitro and In Vivo.
Cao ZX; Wen Y; He JL; Huang SZ; Gao F; Guo CJ; Liu QQ; Zheng SW; Gong DY; Li YZ; Zhang RQ; Chen JP; Peng C
Mol Pharmacol; 2019 Nov; 96(5):589-599. PubMed ID: 31462456
[TBL] [Abstract][Full Text] [Related]
39. Nuclear factor of activated T-cells, NFATC1, governs FLT3
Solovey M; Wang Y; Michel C; Metzeler KH; Herold T; Göthert JR; Ellenrieder V; Hessmann E; Gattenlöhner S; Neubauer A; Pavlinic D; Benes V; Rupp O; Burchert A
J Hematol Oncol; 2019 Jul; 12(1):72. PubMed ID: 31286998
[TBL] [Abstract][Full Text] [Related]
40. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]